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Abstract—Heart failure is associated with death of cardiomyocytes leading to loss of contractility. Previous studies using
membrane-targeted Akt (myristolated-Akt), an enzyme involved in antiapoptotic signaling, showed inhibition of cell
death and prevention of pathogenesis induced by cardiomyopathic stimuli. However, recent studies by our group have
found accumulation of activated Akt in the nucleus, suggesting that biologically relevant target(s) of Akt activity may
be located there. To test this hypothesis, a targeted Akt construct was created to determine the antiapoptotic action of
nuclear Akt accumulation. Nuclear localization of the adenovirally encoded Akt construct was confirmed by confocal
microscopy. Cardiomyocytes expressing nuclear-targeted Akt showed no evidence of morphological remodeling such
as altered myofibril density or hypertrophy. Nuclear-targeted Akt significantly elevated levels of phospho-Akt and
kinase activity and inhibited apoptosis as effectively as myristolated-Akt in hypoxia-induced cell death. Transgenic
overexpression of nuclear-targeted Akt did not result in hypertrophic remodeling, altered cardiomyocyte DNA content
or nucleation, or enhanced phosphorylation of typical cytoplasmic Akt substrates, yet transgenic hearts were protected
from ischemia-reperfusion injury. Gene array analyses demonstrated changes in the transcriptional profile of Akt/nuc
hearts compared with nontransgenic controls distinct from prior characterizations of Akt expression in transgenic hearts.
Collectively, these experiments show that targeting of Akt to the nucleus mediates inhibition of apoptosis without
hypertrophic remodeling, opening new possibilities for therapeutic applications of nuclear-targeted Akt to inhibit cell
death associated with heart disease. (Circ Res. 2004;94:884-891.)
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Programmed cell death, also known as apoptosis, occurs ina wide variety of cardiovascular disorders and is now
recognized as a fundamental process that contributes to
deterioration of cardiac function.1 Controlling myocardial cell
loss by enhancing survival signal cascades leading to inhibi-
tion of apoptosis could be a useful strategy for slowing
development of heart failure. Among numerous signaling
pathways involved in regulation of cell survival cascades, the
serine-threonine kinase Akt/PKB plays a crucial role.2,3
Cytosolic Akt is activated by phosphorylation mediated by
PI3-kinase and 3-phosphoinositide–dependent kinase (PDK)
that are stimulated by growth factors such as IGF-1 at cell
membrane.4–7 After activation, Akt accumulates in the nu-
cleus, phosphorylates multiple protein substrates, and is
thought to regulate gene transcription.8–19 Akt activation also
promotes glucose transport,20 glycogen21 and protein22,23
synthesis, and withdrawal from the cell cycle.24,25 However,
cardiovascular-related Akt research has been predominantly
fueled by the ability of activated Akt to enhance cell survival
by promoting signaling cascades that lead to inhibition of
cardiomyocyte apoptosis in vitro26–28 and in vivo.26,29,30
Akt-associated pathways and substrate proteins leading to
antiapoptotic effects and cellular survival are complex, but
recent studies suggest that biologically relevant targets of
phospho-Akt action are localized in the nucleus.8–16 We
previously reported a 2-fold higher level of phospho-Akt in
cardiomyocyte nuclei of premenopausal women relative to
men or postmenopausal women, and that estrogenic stimula-
tion promotes accumulation of activated Akt in the nucleus.31
Higher levels of nuclear Akt activity in women and in
estrogen-treated cardiomyocytes could partially account for
the gender-associated differential in development of heart
failure in women compared with middle-aged men.32
Protection from apoptotic stimuli in cardiomyocytes has
been demonstrated using adenovirally mediated gene transfer
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of constitutively activated (myristolated) Akt.26–30 However,
the constitutively activated form of Akt preferentially local-
izes at the cell membrane, resulting in supraphysiological
levels of kinase activity.33–35 Constitutively activated forms
of PI3-kinase or Akt induce oncogenic transformation in
fibroblasts,35 as well as cardiac hypertrophy and/or fail-
ure,36–40 raising issues of feasibility and safety concerning the
utility of Akt for therapeutic treatment of heart disease.
Antiapoptotic therapy for cardiomyocytes depends on suc-
cessful inhibition of cell death without promoting activation
of compensatory pathways leading to deleterious hypertro-
phic remodeling or cellular growth. Because biologically
relevant target proteins of Akt kinase associated with inhibi-
tion of apoptosis may be localized in the nucleus,8–15,34 we
explored the hypothesis that protection could be mediated by a
nuclear-targeted Akt protein construct (Akt/nuc). Our results
demonstrate the cytoprotective effects of Akt/nuc and support
the potential interventional use of Akt/nuc as interventional
treatment to combat apoptosis leading to heart failure.
Materials and Methods
Experimental methods are detailed in the expanded Materials and
Methods in the online data supplement (available at http://circres.
ahajournals.org). Briefly, an adenovirus expressing mouse cellular
Akt upstream of nuclear localization signals (Akt/nuc) was created
by PCR-based cloning technique with AdMax (MicroBix) Cre-
mediated site-specific recombination system. Cell culture, immuno-
histochemistry and confocal microscopy, nuclear extract and cytosol
preparation, immunoblot and kinase assays were previously de-
scribed.31 In vitro apoptosis was induced by staurosoprine,
2-deoxyglucose, or hypoxia and was quantified by TUNEL staining
or PARP cleavage detection. The transgene for creation of nuclear-
targeted Akt mice was created by subcloning nuclear-targeted Akt
cDNA construct downstream of the mouse -myosin heavy chain
gene promoter. The mouse model of myocardial infarction and
quantification of infarct area have been previously described.49
Microarray analysis was performed by using oligonucleotide mi-
croarray chips containing 70 mer probes for 16 463 mouse genes.
Results
Construction of Nuclear-Targeted Akt Adenovirus
and Verification of Expression
Akt was targeted to the nucleus by cloning full-length
wild-type mouse Akt cDNA upstream of three in-frame
nuclear localization signal (NLS) sequences. Akt/nuc protein
was distinguished from endogenous Akt by a 3 myc-tag
(Figure 1A). The combined Akt-NLS-myc was subsequently
subcloned into an adenoviral expression vector for efficient
introduction of Akt/nuc into cardiomyocytes. Infection of
neonatal rat cardiomyocyte cultures leads to nuclear accumu-
lation of the adenovirally encoded Akt/nuc as demonstrated
by both confocal microscopy (Figure 1B) and immunoblot
with anti-myc antibody (Figure 1C).
Phosphorylated Akt/nuc Accumulates in the
Nucleus of Infected Cardiomyocytes
Localization of phospho-Akt308 was performed on infected
cardiomyocytes to determine the phosphorylation status of
Akt at residue T308 corresponding to activation.2,3 Accumula-
tion of Akt/nuc signal was confirmed by confocal microscopy
of infected cardiomyocytes labeled with anti-Akt antibody
(Figures 1D3 and 1D4) versus cells expressing nuclear
localized -gal as a negative control (Figures 1D1 and 1D2).
Comparably prepared cells labeled with anti–phospho-Akt308
antibody also show nuclear immunoreactivity (Figures 1D6
and 1D7; green), consistent with activation of the adenovi-
rally encoded Akt/nuc. In comparison, infection with either
Akt/wt or Akt/myr resulted in predominantly cytosolic and/or
membrane-associated Akt immunoreactivity with minimal
nuclear labeling (data not shown).
Nuclear Extracts Show Elevation of Akt and
Phospho-Akt After Infection With Akt/nuc Adenovirus
Nuclear accumulation of Akt/nuc prompted quantitative anal-
ysis to compare levels of Akt and phospho-Akt between
Figure 1. Schematic diagram of Akt/nuc cDNA, confirmation of
protein expression, nuclear accumulation of Akt/nuc protein,
kinase activity in the nucleus after infection of cultured cardio-
myocytes. A, Organization of the DNA construct used for target-
ing of Akt to the nucleus. B, Confocal microscopy of cardiomyo-
cytes labeled with anti-myc antibody (green) after infection with
adenovirus encoding either -gal or Akt/nuc. Sarcomeric actin
was labeled with phalloidin (red) to identify cardiomyocytes.
Bar5 m. C, Immunoblot of cultured neonatal rat cardiomyo-
cytes that were uninfected (control) or infected with adenovi-
ruses producing -gal or Akt/nuc. D, Confocal microscopy
shows expression, localization, and phosphorylation of the Akt/
nuc protein in neonatal rat cardiomyocytes labeled with phalloi-
din (red) to show sarcomeric actin organization and various anti-
Akt antibodies as follows: (1 to 7) Cells labeled with antibody to
Akt (green) after infection with adenovirus encoding -gal (1 and
2) and Akt/nuc (3 and 4); cells labeled with antibody to
phospho-Akt308 (green) after infection with adenovirus encoding
-gal (5) and Akt/nuc (6 and 7). All nuclei in 5 to 7 were labeled
with TOPRO stain (blue). Bar5 m for all micrographs. E, Im-
munoblot analysis of nuclear extracts from neonatal rat cardio-
myocyte cultures infected with adenoviruses expressing either
irrelevant -gal or Akt/nuc. Lysate were labeled with antibodies
to total Akt, phospho-specific Akt T308, or phospho-specific Akt
S473. Signal intensities were standardized relative to histone pro-
tein to compensate for minor variations in protein loading (not
shown). F, Akt/nuc kinase exhibits phosphorylation activity.
Substrate phosphorylation assay for Akt kinase using nuclear
extracts prepared from cultured neonatal rat cardiomyocytes
infected with adenoviruses producing -gal (control) or Akt/nuc.
Immunoblot analysis shows Akt activity measured by phosphor-
ylation of a GSK substrate detected by binding of anti–
phospho-GSK (p-GSK) antibody.
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cardiomyocyte cultures expressing Akt/nuc versus adenovi-
rus encoding nuclear-localized -gal as a control for nonspe-
cific effects. Nuclear-enriched fractions were prepared and
subjected to immunoblot analysis using antibodies to total
Akt as well as phosphorylation-specific antibodies directed
against sites T308 and S473 that correlate with Akt activation
(Figures 1E). Total Akt level in nucleus was substantially
higher in Akt/nuc-expressing cultures compared with -gal
(64.221.9-fold). The same extracts also showed increases
for both phospho-Akt308 and phospho-Akt473 level (2.00.4-
and 4.51.4-fold, respectively) compared with -gal ex-
pressing cardiomyocytes. All of the observed increases in Akt
and phospho-Akt signal resulting from expression of Akt/nuc
were highly significant (P0.01).
Akt/nuc Increases Kinase Activity in the Nucleus
Phosphorylation of Akt correlates with kinase activation, so
substrate phosphorylation analysis was performed on nuclear
extracts of Akt/nuc-expressing cardiomyocyte cultures to
confirm elevation of kinase activity. Akt kinase activity in
immunoprecipitates from nuclear extracts (Figure 1F) shows
significantly increased phospho-GSK signal (2.20.18-fold)
after incubation with extracts from Akt/nuc expressing car-
diomyocytes relative to control cultures expressing nuclear-
localized -gal.
Akt/nuc Does Not Induce Morphological
Remodeling Associated With Hypertrophy
Cardiomyocyte cell area measurements were taken to deter-
mine whether accumulation of Akt/nuc causes cardiomyocyte
enlargement as reported for myristolated Akt (Figure 2).
Expression of myristolated Akt significantly enlarged cardio-
myocytes compared with cells that were uninfected (182%,
P0.001) or infected with adenovirus expressing -gal
(199%, P0.001), wild-type Akt (218%, P0.001), or Akt/
nuc (194%, P0.001). Akt/nuc showed no increase in cell
size compared with uninfected or -gal–expressing cardio-
myocytes. Thus, expression of Akt/nuc does not induce
hypertrophic remodeling in cultured cardiomyocytes.
Akt/nuc Inhibits Apoptosis Induced by
Staurosporine or Deoxyglucose
To determine whether Akt/nuc promotes cell survival in
cardiomyocytes, cultured myocardial cells expressing Akt/
nuc were treated either with 1.0 mmol/L deoxyglucose or
0.25 mol/L staurosporine. Apoptotic DNA fragmentation
was detected by TUNEL assay. Akt/nuc significantly inhib-
ited apoptosis after treatment with deoxyglucose compared
Figure 3. Expression of Akt/nuc inhibits apoptosis of cardiomyo-
cytes treated with staurosporine, deoxyglucose, or hypoxia.
Results of TUNEL assay (A), PARP cleavage (B), or hypoxia (C). A,
For TUNEL assay, cardiomyocyte cultures were infected with
adenoviruses expressing nuclear-localized -gal (black columns) or
Akt/nuc (gray columns) overnight followed by treatment with
1.0 mmol/L deoxyglucose or 0.25 mol/L staurosporine to induce
apoptosis. Results shown are derived from a minimum of 4 sepa-
rate experiments. B, For PARP cleavage experiments, cardiomyo-
cyte cultures were infected with adenoviruses expressing nuclear-
localized -gal or Akt/nuc overnight followed by treatment with
1.0 mmol/L deoxyglucose or 0.25 mmol/L staurosporine to induce
apoptosis. Results are expressed as the percentage reduction of
PARP cleavage in Akt/nuc-expressing cells relative to nuclear-
localized -gal expressing cultures. C, ELISA-based immunoassay
quantitation of DNA fragmentation in cardiomyocytes infected with
adenovirus encoding EGFP, Akt/myr, or Akt/nuc at different pfu/cell
ratios. Results are expressed in optical density (O.D.) units based
on colorimetric reaction. * and ** indicate statistical difference
(P0.05 and P0.01) vs EGFP-infected cells, respectively.
Figure 2. Cardiomyocyte size is not affected by Akt/nuc overex-
pression. Bar graph representing cross-sectional cell area mea-
surements from cardiomyocytes that were either uninfected or
infected with adenoviruses as indicated along the x-axis (-gal,
Akt/wt, Akt/nuc, and Akt myr). A minimum of 25 cells were mea-
sured for each population. Measurements are presented in m2.
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with cells expressing -gal (Figure 3A; 82.211.2 versus
46.816.6%; P0.01). Akt/nuc also inhibited apoptosis of
staurosporine-treated cells (Figure 3A; 78.017.5% versus
40.321.6%; P0.01).
To test whether Akt/nuc prevents apoptosis via downregu-
lation of caspases, we analyzed cleavage of poly ADP-ribose
polymerase (PARP), a 116-kDa nuclear DNA repair enzyme
substrate of caspase-3 during apoptosis. Cleavage of PARP
by caspase-3 yields an 85-kDa fragment, indicating activation
of caspases. Cardiomyocyte cultures were infected with
Akt/nuc and then treated to induce apoptosis with staurospo-
rine or deoxyglucose the next day. Level of PARP cleavage in
Akt/nuc-expressing cells was standardized relative to identi-
cally treated cells infected with adenovirus expressing -gal.
In the absence of apoptotic stimulation, cleaved PARP signal
was decreased 22% in cultures expressing Akt/nuc relative to
nuclear-localized -gal (Figure 3B). In comparison, Akt/nuc
was capable of decreasing PARP cleavage by 55% and 44%
in cultures treated with either staurosporine or deoxyglucose,
respectively. These reductions of PARP cleavage were highly
significant (P0.01), demonstrating that Akt/nuc can inhibit
apoptotic activation of caspases.
Akt/nuc Inhibits Apoptosis of Hypoxic Cardiomyocytes
To examine whether Akt/nuc effectively inhibited cardio-
myocyte apoptosis as well as constitutively activated (myris-
tolated) Akt, we infected cultured cardiomyocytes with ade-
novirus encoding either Akt/nuc or myristolated-Akt and the
cells were subjected to hypoxia for 24 hours (Figure 3C).
Infection of cardiomyocytes with myristolated-Akt at a mul-
tiplicity of infection (MOI) of 80 plaque-forming units (pfu)
per cell significantly inhibited apoptosis of hypoxic cardio-
myocytes when being compared with myocytes infected with
adenovirus encoding EGFP as a control (less DNA fragmen-
tation; P0.05). Infection of Akt/nuc adenovirus substan-
tially blocked apoptosis of hypoxic cardiomyocytes even at a
concentration of 20 pfu/cell (less DNA fragmentation versus
enhanced green-fluorescent protein (EGFP)-infected cells;
P0.05). Apoptosis was most effectively inhibited with
Akt/nuc at a concentration of 40 pfu/cell (P0.01).
Generation of Transgenic Mice Cardiac-Specific
Expression of Nuclear-Targeted Akt
Transgenic mice expressing nuclear-targeted Akt driven by
-myosin heavy chain gene promoter (Figure 4A) were
created to determine whether Akt/nuc enhances survival of
cardiomyocytes in vivo. Expression of Akt/nuc in transgenic
mice was confirmed by immunostaining and immunoblot by
using Akt and phospho-Akt antibodies (Figures 4B and 4C).
Transgenic mice (lines 71 and 41) show higher expression of
Akt compared with non-transgenic mice. Transgenic Akt/nuc
bands show higher apparent mobility because the Akt cDNA
is fused with the myc tag and nuclear localization sequence.
Transgenic mice were healthy without increases in heart
weight/body weight ratio and myocardial cell size compared
with nontransgenic mice (data not shown).
Akt/nuc Protects Against Ischemia-Reperfusion Injury
To test whether cardiac-specific transgenic expression of
nuclear-targeted Akt was sufficient to protect the heart
against pathological damage in vivo, mice were subjected to
a 30-minute coronary occlusion followed by 24-hour reper-
fusion. Myocardial infarct size was significantly reduced in
Akt/nuc transgenic mice (5.8% of region at risk, P0.0009
versus NTG) as compared with nontransgenic controls (21%
of region at risk; Figures 4D and 4E), demonstrating that
Akt/nuc protects against ischemia-reperfusion injury.
Akt/nuc Does Not Increase Phosphorylation of
Cytoplasmic Akt Substrates
The possibility that Akt/nuc promotes enhanced phosphory-
lation of cytoplasmic substrates was examined by immuno-
blot assessment of two canonical targets of activated Akt:
GSK-3 and BAD. In both cases, phosphorylation levels at
residues known to be Akt targets in cardiomyocytes were
Figure 4. Transgenic expression of nuclear-targeted Akt in vivo
protected the heart from ischemia-reperfusion injury. A, Trans-
genic DNA construct used for targeting of Akt to the nucleus.
Full-length wild-type mouse Akt cDNA was cloned upstream of
a myc-tag (red) and nuclear localization sequences (NLS, green)
and was driven by -myosin heavy chain gene promoter. B,
Immunohistochemical study of hearts taken from nontransgenic
mice (A, D, and E) and Akt/nuc transgenic mice (B, C, E, and F)
simultaneously stained with antibody against total Akt (A, B, and
C, green), phospho-Akt (D, E, F, and G, green) and propidium
iodide (A through G, red). C, Immunoblot of protein extracted
from the nuclear fraction of the mouse heart stained with anti-
bodies against total Akt (top panel) and myc-tag (bottom panel).
D, Mice underwent a 30-minute coronary occlusion followed by
a 24-hour reperfusion. After postmortem perfusion, the nonis-
chemic portion of the left ventricle was stained blue, the viable
tissue within the region at risk bright red, and the infarcted tis-
sue appears light yellow. Representative transverse heart sec-
tions from NTG mice (D, left) demonstrate confluent regions of
infarction, whereas Akt-nuc transgenic mice (D, right) exhibit
only sporadic areas of infarction. E, Graphic representation of
myocardial infarct size in NTG mice and nuclear-targeted trans-
genic mice, expressed as a percentage of the region at risk. ,
individual mice; , mean SE.
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comparable between nontransgenic WT and Akt/nuc trans-
genic mice (Figure 5). In comparison, phosphorylation levels
for GSK-3 and BAD were increased in cardiomyocytes
isolated from transgenic mice created with cardiac-specific
expression of IGF-1, a known stimulus for Akt activation.
Similarly, overexpression of myristolated Akt promotes en-
hanced phosphorylation of GSK-3 and BAD, confirming
these proteins as substrates for Akt-mediated phosphoryla-
tion. These results indicate phosphorylation of typical cyto-
plasmic target substrates in Akt/nuc transgenic mouse hearts
are not increased, supporting the postulate that Akt/nuc is
efficiently targeted to the nucleus.
Akt/nuc Does Not Influence Cardiomyocyte Ploidy
or DNA Content
The potential for Akt/nuc to promote nuclear division and
DNA synthesis was assessed by determination of nuclei per
cardiomyocyte and cardiomyocyte DNA content (Figures 6A
and 6B, respectively). In both cases, populations of cardio-
myocytes isolated from Akt/nuc hearts were comparable to
those of nontransgenic WT mice, indicating that expression
of Akt/nuc does not promote nuclear replication or DNA
synthesis.
Akt/nuc Alters Transcriptional Profile in
Transgenic Mouse Hearts
Gene expression in Akt/nuc mouse hearts was compared with
normal nontransgenic mice by gene array profiling. Age- and
gender-matched hearts were grouped for analysis as samples
of pooled Akt/nuc hearts (Tg A3 hearts, Tg B4 hearts)
and nontransgenic hearts (WT C3 hearts, WT D4 hearts).
Tg A or Tg B samples were hybridized in quadruplicate (with
Cy3 and Cy5 dye reversal) to WT C and in quadruplicate to
WT D. Intensity ratio values that differed from the median
with a confidence interval 95% were compiled. The Table
presents nonexpression sequence-tagged (est) genes that were
significantly altered in at least three of four hybridizations for
each group. For example, Tg A versus WT C showed
decreased expression in at least three of four separate hybrid-
izations for prostaglandin D2 synthase (PDGS; lipocalin) and
protein tyrosine phosphatase, nonreceptor type 2 (PTP) with
increased expression for gastric inhibitory peptide (GIP).
PDGS was significantly downregulated in all four groups,
and PTP was also downregulated in three of four groups as
confirmed by RT-PCR. Although GIP was significantly
upregulated in all four groups, GIP was not detectable in
Akt/nuc heart RNA using RT-PCR suggesting cross-
hybridization occurred with another mRNA possessing a
similar coding sequence. Four additional genes were differ-
entially regulated in one of the four groups (not shown).
Subsequent RT-PCR validation tests confirmed one of these
genes, connective tissue growth factor (CTGF), was down-
regulated in three of the four comparison groups.
Figure 5. Akt/nuc does not enhance phosphorylation of cyto-
plasmic target substrates. Immunoblot analysis of heart lysates
shows phosphorylation levels for GSK-3 (top) or BAD (middle)
are not markedly enhanced by expression of Akt/nuc. In con-
trast, phosphorylation of these proteins is increased in trans-
genic mice expressing IGF-1 or in cultured cardiomyocytes after
adenoviral-mediated overexpression of Akt/myr. Equivalent
loading of lanes in immunoblot is demonstrated by comparable
levels of actin in all samples (bottom).
Figure 6. Akt/nuc does not affect cell nucleation or DNA con-
tent. A, Distribution of nuclear number per cardiomyocyte in
nontransgenic control (black bars) or Akt/nuc (gray bars) is com-
parable except for a slightly higher fraction of mononucleated
cells that are more prevalent in the Akt/nuc (*P0.05). B, Histo-
gram distribution demonstrates no difference in DNA content
per cell between nontransgenic control (WT), Akt/nuc, or lym-
phocytes as a normal diploid cell reference.
Fold Change in Gene Expression Determined by Microarray and
Confirmed by RT-PCR
Tg A vs WT C Tg A vs WT D Tg B vs WT C Tg B vs WT D
GIP 1.571 (ND) 1.446 (ND) 1.526 (ND) 1.418 (ND)
PGDS 0.486 (0.139) 0.728 (0.403) 0.553 (0.192) 0.743 (0.587)
PTP 0.642 (0.625) 0.756 (0.863) NS (0.747) 0.743 (0.884)
CTGF NS (0.793) 0.749 (0.637) NS (1.014) NS (0.814)
Fold changes in gene expression that were significant at the 95% confidence
level are shown. NS indicates not significant for microarray at 95% confidence
level. Values in parentheses were determined by RT-PCR; ND, not detectable.
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Discussion
Akt myocardial biology involving overexpression has been
studied with constitutively activated26,27,29,30,38,39 or dominant-
negative kinase.38 Characterizing Akt activation in the myocar-
dium produces two recurring themes: promotion of growth and
antiapoptotic activity. Promotion of growth is observed in vivo,
particularly in assessment of postnatal cardiac enlargement
resulting from transgenic expression of Akt kinase in the
myocardium,38–40 although hypertrophic growth of cardiomyo-
cytes was also reported.36 Antiapoptotic effects are a consistent
finding both in vivo26,29 and in vitro.26,27 Alternatively, myocar-
dial Akt signaling has been examined through manipulation of
insulin41 or IGF-1 stimulation.31,42 Shared phenotypic character-
istics of apoptotic resistance and hypercellularity were observed
after cardiac-specific overexpression of IGF-143 or constitutive
Akt activation.38 – 40 However, other aspects of Akt-
overexpression showing hypertrophy,38–40 depressed contractile
function,38–40 and heart failure39 are not readily reconciled with
the phenotype of IGF-1 overexpressing transgenics. One poten-
tial explanation for the phenotypic differences between consti-
tutively activated Akt- versus IGF-1 overexpression in the heart
may be the degree and distribution of Akt activity, prompting
our investigation of the consequences for targeted activation of
Akt in the nucleus of cardiomyocytes.
Hearts from IGF-1–overexpressing mice show accumula-
tion of activated Akt in the nucleus compared with nontrans-
genic mice, which show differential nuclear Akt activity
correlating with gender.31 Akt does not possess an inherent
nuclear localization signal sequence and activated Akt may
depend on cofactors such as TCL1 that mediate nuclear
localization by facilitating Akt oligomerization.44,45 TCL1 is
an oncogene of human T-cell leukemia, but related molecules
responsible for nuclear translocation of Akt may exist in
cardiomyocytes. Numerous cell survival and cell cycle tran-
scription factor substrates for Akt phosphorylation are located
in the nucleus, including forkhead family proteins,9,10 SRK,13
E2F,14 CREB,15 TSC2,46 p21Cip/WAF1,47 and telomerase
reverse transcriptase.48 In fact, Akt/nuc enhances telomerase
activity and antagonizes the phenotypic changes characteris-
tic of cardiomyocyte aging and senescence much better than
wild-type Akt (unpublished results, 2004). Studies to deter-
mine the ability of cardiac-specific expression of Akt/nuc to
antagonize aging in the myocardium are in progress and thus
far Akt/nuc expression in transgenic mice to over 1 year of
age does not provoke overt cardiomyopathic effects.
Activated Akt in cardiomyocytes localizes to the nucleus
and estrogenic stimulation increased nuclear accumulation of
activated Akt as well as cytoplasmic localization of forkhead
transcription factors.31 Although Akt/nuc successfully pro-
motes cell survival, the expression of cellular Akt (nonacti-
vated form) in a previous study did not inhibit apoptosis
without stimulation of IGF-1.26 In comparison, the subcellu-
lar distribution of constitutively active Akt is dispersed
among the cellular components with 40% on the cell mem-
branes, 30% in the nucleus, and 30% in the cytosol, whereas
overexpression of cellular wild-type Akt accumulates primar-
ily (90%) in the cytosol.33 Furthermore, Akt/nuc inhibited
hypoxia-induced apoptosis as efficiently as (or better than)
myristolated Akt. However, phosphorylation of cytoplasmic
targets including the apoptotic mediator BAD were un-
changed in Akt/nuc transgenic hearts (Figure 5). These
findings support our postulate that relevant targets for Akt
phosphorylation that mediate cellular survival are present in
nucleus.
Potent antiapoptotic effects of Akt/nuc meet and surpass
the level of protection afforded by Akt/myr both in vitro and
in vivo (Figures 3 and 4). Cardiac-specific transgenesis of
nuclear-targeted Akt produced a profound infarct-sparing
effect (70% reduction versus wild type). Akt/nuc affords
protection comparable in magnitude to early ischemic pre-
conditioning (75% reduction),49 the most powerful cardio-
protective modality that has been described to date.
Two genes found to be downregulated in Akt/nuc trans-
genic hearts are PGDS and PTP, which are novel and distinct
from genes previously reported to be influenced by expres-
sion of activated Akt in the myocardium.50 Estrogen has been
reported to increase PGDS mRNA in rat brain,51 and we
previously found estrogen increases nuclear localization of
Akt.31 Complex regulation of estrogen of PGDS51 and signif-
icant differences in experimental design could account for
decreased PDGS expression in our study versus increased
estrogen-mediated expression in the brain. Thus, PGDS may
be an interesting estrogen-regulated gene in the heart. PTPN2
(also known as TC-PTP) is homologous to PTP-1B.52
PTP-1B influences PI3-kinase,53 insulin-mediated signal-
ing,54,55 and downregulation enhances IGF-1–mediated cell
survival.56,57 Thus, decreased expression of PTP could help
promote enhanced cardiomyocyte survival in Akt/nuc trans-
genic mice.
Ideally, therapeutic intervention in apoptotic cardiomyo-
cyte death should exert minimal deleterious effects on car-
diomyocyte structure or function. Experimental prevention of
cell death in acute cardiac injury associated with apoptosis
has been attempted using membrane-targeted myristolated
Akt,26–30 but supraphysiological levels of constitutively acti-
vated kinase34,35 cause cardiomyocyte hypertrophy36,38 and
cardiomyopathic effects.38,39 Potent survival signaling with-
out promoting hypertrophic remodeling or DNA synthesis
makes Akt/nuc an interesting candidate for therapeutic inter-
vention against cardiomyopathic injuries resulting from is-
chemic heart disease, chronic pressure or volume overload,
hypoxia, or anticancer drugs.
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